EFTA01453440

might saddle state Medicaid programs with steep costs. US is the only major health-care market remaining without any meaningful drug price controls -- increased risk for the sector once the Congress gets involved, especially if focused primarily on pricing. Description Trade Date Quantity Last Prices Unit Cost Market Value Unrealized G/L SANGAIIO BIOSCIENCES 05/28/2013 50,000.00 5 19.80 $ 8.44 $ 990,000.00 $ 567,786.00 BIOGEN 02/14/2012 2,095.30 $ 312.60 $ 119.55 $ 654,897.00 $ 404;142.05 FOUNDATION MEDICINE 01/13/2014 25,000.00 $ 36.40 $ 27.51 910,000.00 $ 222,336.50 GILEAD SCIENCES INC 2/5/14, 3/7/14 8,100.30 $ 72.13 $ 79.41 $ 584,253.00 $ (58,951.00) ARIAD PHARMACEUTICALS 2/14/12, 1/24/13 16,535.00 5 7.60 $ 17.60 $ 125,666.00 $ (165,331.40) Total Biotec $3,264,816.00 $ 970,282.15 Nasda. Biotech Index -1 r Price Histo NBI On 24 Mar 2537.52 2587.92 L 2434.16 2499.44 95) Save As 99 Actions - 97) Edit - 9$ Table Line Chart It!. corrpare <7., oti .70 3Y SY Max Daily • C Security/Stuffy Event O • Track Annotate 'fr2 News O, Zoom NBI Index 03;25/2013 10 30 1M 01;2512014 o• Last Price 2499.44 T High on 02/25/14 2854.26 +- Average 2155.07 1 Low on 03/25/13 1619.16 on Volume 83.0411 SMAVG (15) 62.329M IflHIIiuiiww . I Jun Sep Dec Mar 2013 2014 2800 7600 2499.44 2400 2200 2000 1800 1600 0 Ariad - 1yr Price History CONFIDENTIAL - PURSUANT TO FED. R. CRIM. P. 6(e) DB-SDNY-0 111022 CONFIDENTIAL SDNY_GM_00257206 EFTA01453440